Pfizer has revealed that it will take a more “opportunistic” approach to biosimilar investments in future, as the firm reported a staggering 88% operational growth and 93% overall growth in its biosimilars business globally in the second quarter of 2021. The company’s biosimilars segment clocked in $559m in Q2, compared to $289m in the prior-year period.
According to Pfizer, the growth in biosimilars was “primarily driven by recent oncology monoclonal antibody biosimilar launches of Zirabev (bevacizumab), Ruxience (rituximab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the US,